NCT06442462: An ongoing trial by Spinogenix
This trial is ongoing. It must report results 1 year from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06442462 |
|---|---|
| Title | A Randomized, Placebo-controlled, Double-blind Phase 2 Study to Assess the Efficacy, Safety, Tolerability, and Pharmacodynamics of SPG302 in Adult Participants Diagnosed With Schizophrenia |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 1, 2024 |
| Completion date | Dec. 31, 2025 |
| Required reporting date | Dec. 31, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |